|
|
Post by rockstarrick on Dec 8, 2016 13:05:03 GMT -5
|
|
|
|
Post by mnkdorbust on Dec 8, 2016 13:10:29 GMT -5
Not sure why this was just published given the split but shows date of 12/8/16. Pretty much what Al was saying all along. From the article: "According to the news reporters, the research concluded: "In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products." For more information on this research see: Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. Diabetes Technology & Therapeutics, 2016;18(9):574-585. Diabetes Technology & Therapeutics can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - http://www.liebertpub.com; Diabetes Technology & Therapeutics - www.liebertpub.com/overview/diabetes-technology-and-therapeutics/11/)" |
|
|
|
Post by compound26 on Dec 8, 2016 13:20:52 GMT -5
Please note that this is not something new. The news report is just restating the findings in the simulation trial that was run in earlier 2016. www.ncbi.nlm.nih.gov/pubmed/27333446Diabetes Technol Ther. 2016 Sep;18(9):574-85. doi: 10.1089/dia.2016.0128. Epub 2016 Jun 22. Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.Visentin R1, Giegerich C2, Jäger R2, Dahmen R2, Boss A3, Grant M4, Dalla Man C1, Cobelli C1, Klabunde T2. Author information Abstract BACKGROUND: Technosphere(®) insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential benefit of different dosing regimens on postprandial glucose (PPG) control to support the design of further clinical trials. Tested dosing regimens included at-meal or postmeal dosing, or dosing before and after a meal (split dosing). METHODS: Various dosing regimens of TI were compared among one another and to insulin lispro in 100 virtual type-1 patients. Individual doses were identified for each regimen following different titration rules. The resulting postprandial glucose profiles were analyzed to quantify efficacy and the risk for hypoglycemic events. RESULTS: This approach allowed us to assess the benefit/risk for each TI dosing regimen and to compare results with simulations of insulin lispro. We identified a new titration rule for TI that could significantly improve the efficacy of treatment with TI. CONCLUSION: In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products.TRIAL REGISTRATION: ClinicalTrials.gov NCT01445951 NCT01544881. |
|
|
|
Post by promann on Dec 8, 2016 13:24:31 GMT -5
Very strange. Why would Sanofi say anything good about Afrezza! Must be a old article re released |
|
|
|
Post by sayhey24 on Dec 8, 2016 21:24:31 GMT -5
Rick - thanks for posting. If we are correct, the timing makes perfect sense. As they say, hope springs eternal but in the end things always have to make sense.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2016 21:34:33 GMT -5
Rick - thanks for posting. If we are correct, the timing makes perfect sense. As they say, hope springs eternal but in the end things always have to make sense. It was a recycled article and the study was completed when Sanofi had Afrezza - which was until April 2016. Hope springs eternal - lol but should not hope on things that are already clarified. If you are still hoping sanofi is working with google through Onduo to take over afrezza - thats not hope - thats delusional. Hoping Afrezza takes off in the medical community - is hope cos it will happen sooner or later hoping Afrezza cures cancer is delusional |
|
|
|
Post by letitride on Dec 8, 2016 22:35:58 GMT -5
If anything it shows Sanofi fully understood the efficacy of Afrezza and could have given a crap about diabetic healthcare but rather was more concerned with burying Mannkind in its own best interest in my opinion.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2016 23:27:39 GMT -5
If anything it shows Sanofi fully understood the efficacy of Afrezza and could have given a crap about diabetic healthcare but rather was more concerned with burying Mannkind in its own best interest in my opinion.Thats emotional. Corporate companies dont work on emotions. Sanofi spent a lot of $ and it didnt see the equivalent revenue - didnt fit it in new ceo strategy to cover falling lantus revenues ..and they realized its a hard sell ..and cut ties. as simple as that. |
|
|
|
Post by letitride on Dec 9, 2016 7:07:33 GMT -5
Note the missing exclamation mark at the end of my opinion, no emotion just a calculated conclusion. Emotional would have contained the inclusion of an explicative or two not conducive to congenial proboard banter. And an exclamation mark!
|
|
|
|
Post by sportsrancho on Dec 10, 2016 16:28:00 GMT -5
If anything it shows Sanofi fully understood the efficacy of Afrezza and could have given a crap about diabetic healthcare but rather was more concerned with burying Mannkind in its own best interest in my opinion. I think they wanted to buy MNKD. Al said no, so they partnered. Didn't try very hard to sell it. For what ever reason ( new CEO ) and now hope it goes away. Oops! |
|
